BriaCell CEO Letter to Shareholders

Core Insights - BriaCell Therapeutics Corp. has achieved significant milestones in its clinical studies, particularly in the Bria-IMT™ Phase 3 study and the Bria-OTS™ Phase 1/2 study, indicating potential transformative impacts on cancer treatment [1][4][5] Bria-IMT Pivotal Phase 3 Clinical Study - Bria-IMT™ is a targeted cell-based immunotherapy for metastatic breast cancer, currently being tested in combination with an immune checkpoint inhibitor [2] - Over 75 patients have been enrolled across 54 clinical sites in 15 states, including notable cancer centers [3] - Positive recommendations from the Data Safety Monitoring Board (DSMB) have been received, and successful completion of the study could lead to a fast-track application for drug approval [3][6] Bria-IMT Phase 2 Clinical Study - The Phase 2 study has shown survival data superior to the standard of care, with 83% of evaluable patients benefiting from the treatment [5][6] - The average survival for this patient population is under one year, highlighting the urgent need for effective therapies [6] Bria-OTS Phase 1/2 Clinical Study - Bria-OTS is a personalized immunotherapy platform that matches patients' human leukocyte antigens (HLA) to optimize treatment response [8] - A notable case reported 100% resolution of lung metastasis in a patient after two months of Bria-OTS monotherapy [9][10] Financing and Future Outlook - The company raised US$13.8 million through a public offering to support clinical programs and business advancement [13] - The company anticipates sharing further advancements in its clinical programs in the coming months [13][14]